Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Medtronic
Moodys
McKesson
Express Scripts

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLODATEROL HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Olodaterol Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01153711 Relative Bioavailability of of Olodaterol and Ketoconazole Completed Boehringer Ingelheim Phase 1 2010-05-01 This clinical trial is intended to investigate a possible effect of the p-gp inhibitor ketoconazole on the bioavailability of olodaterol
NCT01153724 Relative Bioavailability of Olodaterol and Fluconazole Completed Boehringer Ingelheim Phase 1 2010-05-01 This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol
NCT01311661 A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma Completed Boehringer Ingelheim Phase 2 2011-03-01 This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium or high daily dose).
NCT01428622 Olodaterol Bridging Study in Asthma Withdrawn Boehringer Ingelheim Phase 2 2011-10-01 The aim of the study is to establish the olodaterol dose in the ethanolic fixed dose combination (FDC) with BI 54903 which is equivalent in bronchodilator effect and systemic exposure to the 5 µg olodaterol reference dose in the aqueous inhalation solution (AIS).
NCT01431274 Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Completed Boehringer Ingelheim Phase 3 2011-09-01 The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).
NCT01431287 Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Completed Boehringer Ingelheim Phase 3 2011-09-01 The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components (tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with COPD.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Olodaterol Hydrochloride

Condition Name

Condition Name for Olodaterol Hydrochloride
Intervention Trials
Pulmonary Disease, Chronic Obstructive 29
Asthma 3
Healthy 2
Chronic Obstructive Pulmonary Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Olodaterol Hydrochloride
Intervention Trials
Pulmonary Disease, Chronic Obstructive 31
Lung Diseases 31
Chronic Disease 29
Lung Diseases, Obstructive 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Olodaterol Hydrochloride

Trials by Country

Trials by Country for Olodaterol Hydrochloride
Location Trials
United States 237
Canada 44
Germany 22
United Kingdom 14
Australia 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Olodaterol Hydrochloride
Location Trials
South Carolina 15
Virginia 11
North Carolina 11
Florida 10
Missouri 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Olodaterol Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Olodaterol Hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 15
Phase 2 5
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Olodaterol Hydrochloride
Clinical Trial Phase Trials
Completed 20
Recruiting 9
Not yet recruiting 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Olodaterol Hydrochloride

Sponsor Name

Sponsor Name for Olodaterol Hydrochloride
Sponsor Trials
Boehringer Ingelheim 32
University of Dundee 2
Healthcore 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Olodaterol Hydrochloride
Sponsor Trials
Industry 34
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.